Mikacin Injection
Developed to mitigate complex gram-negative infections to support rapid blood clearing and target bacterial replication.
- Category
- Antibiotics
- Active ingredient
- Amikacin
- Route
- Intravenous use
- Form
- Tablet
- Strengths
- 100mg per 2ml
Prescription and consultation requirements for Mikacin Injection vary by destination and are determined by the fulfilment partner.
Mikacin Injection details
- Conditions
- Severe Bacterial Infections · Septicaemia · Urinary Tract Infections
- Alternative names
- amikacin
- Therapeutic class
- Aminoglycoside Antibiotic
- Pharmacological class
- Protein Synthesis Inhibitor
- Minor side effects
- nausea; headache; vomiting
- Moderate side effects
- mild proteinuria; vestibular dysfunction; rash
- Dosage forms
- Tablet
- Administration route
- Intravenous use
- Supply category
- Prescription-only medicine (POM)
- Manufacturer
- Aristo Pharmaceuticals
- Onset Time
- 30 minutes
- Duration
- 12 hours
- Storage instructions
- Store below 25°C.
- Drug interactions
- Furosemide; Amphotericin B; Vancomycin
- Age restrictions
- Approved for infants, children, and adults.
Contraindications
history of aminoglycoside-induced ototoxicity; severe hypersensitivity to amikacin
Serious side effects
severe nephrotoxicity, requires immediate medical attention; permanent ototoxicity, requires immediate medical attention; neuromuscular blockade, requires immediate medical attention
Patient summary
developed to mitigate complex gram-negative infections to support rapid blood clearing and target bacterial replication.
Mechanism of action
Binds to the 30S ribosomal subunit of susceptible bacteria, causing code translation errors that halt protein synthesis.
Pregnancy and breastfeeding
TGA Category D: High risk of congenital deafness in fetus. Avoid unless essential. Breastfeeding: Compatible.